Research Article
Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes
Figure 3
Levels of proinflammatory parameters in individuals with type 1 diabetes, before and after treatment with empagliflozin 25 mg daily (EMPA), metformin 2000 mg daily (MET), empagliflozin-metformin combination (EMPA-MET COMB), or in control (CTRL) groups: (a) C-reactive protein (CRP) and (b) interleukin-6 (IL-6). represents ; represents , and represents .
(a) |
(b) |